

CORPORATE STATEMENT ON BOTOX® ASSAYS

BOTOX® (botulinum toxin type A) is, first and foremost, an important medicine that over the last 15 years of clinical use has helped millions of patients with serious medical conditions worldwide. In the U.S., BOTOX® is approved for the treatment of four debilitating conditions, including two eye disorders that can lead to functional blindness, cervical dystonia which is a painful movement disorder affecting the head and neck, and excessive underarm sweating. Worldwide, it is approved for twenty different indications in more than seventy-five countries, and the therapeutic use of BOTOX® accounts for the majority of all BOTOX® use.

Currently, all pharmaceutical manufacturers are required by the Food and Drug Administration (FDA) in the United States and by other worldwide health regulatory agencies to protect patients and consumers by assuring product safety and efficacy through animal testing and other methods. BOTOX® is unique among medical therapies in that it is a biological product, which means that it is derived from natural sources – in this case, from the bacterium *C. botulinum*. When manufacturing biological products, testing is particularly critical to ensuring the consistent safety and efficacy of each batch of product.

Allergan has the responsibility to assure that our products are safe in humans. Currently, Allergan is required by regulatory agencies around the world, such as the FDA, as part of the final manufacturing stages of BOTOX®, to use laboratory animals in an assay process. While we use alternative methods to animal research and testing whenever possible, there are no FDA-validated, safe alternatives capable of completely replacing animal research and testing at the present time.

Allergan is committed to the “3R” principles of refinement, reduction and eventual replacement of laboratory animals in the final manufacturing stages of BOTOX®. Over the last five to seven years, we have focused on reducing and refining our assay process with marked success, leading to FDA approval in September 2006 of a revised assay and tightened acceptance criteria for product release that is enabling us to further substantially reduce the number of animals involved in the assay by approximately 50 percent. In the first quarter of 2007, Allergan has submitted two Prior Approval Supplements to the FDA that would further reduce the routine use of animals without decreasing quality assurance. In addition, over the last ten years Allergan has invested more than \$40 million in the development of alternative assays which we hope someday will lead to a non-animal alternative to animal-based assays in the manufacture of our product.

As a global health care company, Allergan is dedicated to providing safe and effective specialty pharmaceutical products and medical devices and improving the lives of patients throughout the world.

###

Updated: April 6, 2007